Prospective Pilot Study Of The Effect Of Rifaximin On B-cell Dysregulation In Cirrhosis Due To Chronic Hepatitis C Infection
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Intestinal infections
- Focus Pharmacodynamics
- 08 Mar 2021 Status changed from active, no longer recruiting to discontinued due to inadequate enrollment prior to expiration date of unreplaceable blinded investigational product.
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.